Epidemiology of Uterine Fibroids: From Menarche to Menopause.

Heavy menstrual bleeding and pelvic pressure are the primary symptoms associated with UL [ 7 ]. Other symptoms include infertility, increased urinary frequency or incontinence, constipation, abdominal bloating, dyspareunia, and fatigue (due to anemia from heavy bleeding) [ 8 , 9 ]. The spectrum and severity of symptoms often depends on the size, location, and number of tumors in the uterus. In an ultrasound-screening study (NIEHS Uterine Fibroid Study, UFS) of a randomly-selected sample of 1,349 women aged 35–49 years enrolled in an urban health plan, risk of self-reported heavy bleeding increased with increasing tumor size [ 24 ]. Studies that use hysteroscopy to examine the uterine cavity have found that UL that distort the cavity (Class 0, I or II submucosal UL) are more closely associated with anemia than other types of UL, even though self-reported bleeding scores do not differ [ 10 , 11 ]. A large proportion of UL are diagnosed in the absence of symptoms. For example, in two prospective cohort studies of women who reported clinically-diagnosed UL, between 29% [ 12 ] and 33% [ 13 ] reported that their UL were found incidentally at the time of a routine pelvic exam or screening for another medical condition. These observations support findings from the UFS, in which 51% of premenopausal women without a clinical diagnosis of UL had ultrasound evidence of UL [ 14 ]. Information on new UL diagnoses may be obtained via self-report, hospital or clinical records, or automated hospital discharge and ambulatory care databases. Ideally, original diagnostic imaging, surgical, and pathology reports are reviewed to validate the diagnosis. For example, self-reported diagnoses were accurate in 93% and 96%, respectively, of women who agreed to release their medical records in a randomly-selected subsample of respondents from two large prospective cohort studies [ 12 , 13 ]. Ultrasound screening studies are becoming increasingly more common. Ultrasound can confirm UL diagnosis and decrease misclassification among the controls who may have asymptomatic UL. These studies provide the most valid information regarding the prevalence of UL [ 9 , 14 – 18 ]. With universal ultrasound screening to classify UL, exposures could be compared not only between symptomatic cases and asymptomatic controls, but also between cases and those controls with uteri free of occult UL, and between controls with and without occult UL. Abdominal [ 19 ] or transvaginal [ 20 , 21 ] ultrasound provides reasonably sensitive, minimally-invasive confirmation of a suspected UL diagnosis relative to histologic evidence [ 19 , 21 ]. However, ultrasound can be a costly addition to a prospective study and the sensitivity of ultrasound wanes when the uterus is enlarged (e.g., pregnancy) or there are multiple UL in the uterus. Ultrasound has a limited ability to detect tumors that are <0.5 cm [ 17 ] makes it difficult to determine the exact onset of disease. Diagnosis of UL by magnetic resonance imaging (MRI) is more expensive, but has better accuracy than ultrasound for mapping UL, in particular for larger uteri or multiple UL [ 21 ]. Only a subset of women with a radiologic diagnosis will ultimately proceed to surgery and histologic confirmation (gold standard). Operative and pathology reports from surgical procedures provide the most precise information regarding the size, location, and number of tumors. However, women who present for hysterectomy generally have failed medical or non-surgical management and represent the symptomatic end of the disease spectrum. Thus, epidemiologic studies that use only hysterectomy cases may identify risk factors operating relatively late in the growth and development of the tumors. Identifying the etiology of UL or options for early intervention is more difficult when the UL have grown to a large size, as they have likely been there for many years. If systematic pelvic imaging is not possible, epidemiologic studies can reduce the impact of bias by including cases newly-diagnosed by ultrasound (or MRI) in addition to those that are confirmed histologically, though this approach will still result in misclassification among controls. Another approach to reducing disease misclassification involves restricting the case definition to self-reported diagnoses of early-onset UL [ 22 , 23 ] because a lower proportion of younger cases will be misclassified as noncases [ 14 ]. UL are often associated with other gynecologic diseases such as endometriosis. Some UL cases will be identified incidentally during examinations prompted by gynecologic symptoms caused by these other conditions. Incidental diagnoses are inevitable because it is difficult to determine whether the symptoms are due to UL or to other pathologic conditions. However, if a characteristic is not related to UL, but is related to a condition that often coexists with these tumors (e.g., adenomyosis), a spurious association with UL could result. To reduce the potential impact of comorbid diagnoses, cases should not be selected preferentially from specialty clinics that treat gynecologic, urologic, or infertility conditions [ 11 , 24 ].

UL are thought to arise from an initiating event related to three pathways: 1) sex steroid hormones, 2) disordered wound healing, and 3) genetic abnormalities [ 33 ]. The initiating event likely causes a myometrial cell to acquire a somatic genetic or epigenetic change that confers increased sensitivity to growth factors or hormones [ 34 , 35 ]. An expansion and growth phase follows, during which cloning of the myometrial cell is accompanied by stimulation of the extracellular environment that provides structure and increased mass to the tumor [ 35 ]. Factors involved in the initiation of UL are being studied using animal models [ 36 – 39 ]. A large prospective study of African-American women aged 23–34 years in Detroit is on-going to study risk factors and exposures present before UL diagnosis (screened with ultrasound) [ 40 , 41 ]. UL occur during the reproductive years and tend to regress after menopause, signifying that estrogen and progesterone play prominent roles in promoting growth [ 33 ]. When compared with normal myometrium, smooth muscle cells in UL exhibit increased expression of steroid hormone receptors, growth factors, and growth factor receptors, most of which are regulated by estrogen [ 35 , 42 ]. While circulating sex steroid hormones are no different in women with and without UL [ 43 ], tissue concentrations of estrogens are higher in leiomyoma tissue. A contributing factor to this elevation is aromatase, which converts testosterone and androstenedione to estrogens. Aromatase [ 44 ] and estrogen receptor [ 45 ] expression is higher in leiomyoma tissue than myometrium. Because of these findings, aromatase inhibitors or selective estrogen receptor modulators are under investigation as therapeutic options [ 46 , 47 ]. In an Eker rat model, estrogen stimulated UL growth while estrogen antagonists, such as Tamoxifen, inhibited growth. Environmental compounds that can interact with estrogen receptors are also being studied [ 22 , 26 , 48 , 49 ]. Clinical studies of UL treated with gonadotropin-releasing hormone (GnRH) agonists provide parallel data from humans. GnRH agonists create a temporary hypoestrogenic state by reducing biologically active gonadotropin secretions of the pituitary gland, which markedly reduces UL size [ 50 ]. Progesterone has recently become a focus of research in UL development and growth [ 51 ], and may be the primary hormone stimulating UL growth [ 52 , 53 ]. In in vivo models, progesterone and the progesterone receptor directly induced growth, likely through the production of extracellular matrix via down-regulation of a tumor suppressor [ 53 – 55 ]. During the secretory phase of the menstrual cycle when progesterone is highest, anti-apoptotic proto-oncogene bcl -2 activity in UL is highest [ 56 – 58 ]. Further, the proliferative activity of UL appears to be higher with medroxyprogesterone acetate (MPA) use compared with other combined oral contraceptive or no hormonal contraception use [ 59 ]. UL proliferation is higher in postemenopausal women receiving combined estrogen and progesterone therapy compared with estrogen therapy alone [ 57 ]. A role of progesterone in UL growth also is supported by most studies of UL treated with progesterone inhibitors. The progesterone receptor antagonist, mifepristone, causes UL shrinkage in a dose-response fashion [ 60 ]; however, therapeutic trials have been limited by adverse endometrial changes [ 61 ]. Progesterone receptor modulators, which have mixed agonist/antagonist effects, reduce UL symptoms in clinical trials [ 62 ]. Ulipristal acetate, a selective progesterone receptor modulator, has been shown to effectively reduce UL size and control UL-related symptoms with similar efficacy to GnRH agonists, and with less hot flashes [ 63 , 64 ]. This medication is approved in Europe and Canada for preoperative treatment of UL. Repeated 12-week courses were shown to be effective and safe leading to the potential for preventative medical therapy for UL [ 65 ]. The expression of various growth factors is higher in UL than normal myometrium. Vascular endothelial growth factor-A (VEGF-A) has been well-studied because of its role in angiogenesis, which is important for tumor growth and cell proliferation. VEGF expression is influenced by estrogen and progesterone and is higher in UL than myometrium [ 43 ]. Fibroblast growth factor has effects on endothelium, smooth muscle cells, and fibroblasts and may be preferentially expressed in extracellular matrix [ 43 ]. Similarly, insulin-like growth factor-1 (IGF-1) is higher in leiomyoma tissue and may be regulated by estrogen and autocrine control [ 35 ]. IGF-1 stimulates leiomyocyte proliferation, but elevated circulating levels are not associated with tumor prevalence [ 66 ]. One of the most studied growth factors is transforming growth factor-beta (TGF-β), which induces extracellular matrix formation in UL through several signaling pathways [ 67 – 69 ]. The TGF-β pathway also plays a role in disordered wound healing which may lead to tumorigenesis [ 68 , 70 ]. Myometrial injury causes growth factor changes that increase cellular proliferation, decrease apoptosis, and increase extracellular matrix production [ 71 ]. Fibrous thickening of tissue (myometrial hyperplasia) is associated with seedling leiomyomas, a leiomyoma precursor [ 72 ]. The inhibition of TGF-β pathways appears to be effective in decreasing growth and bulk of extracellular matrix; current investigations into these pathways may elucidate potential preventive factors. The well-documented racial disparity in UL prevalence and the increased familial aggregation of UL indicate that genetic factors may underlie UL formation. Pathology data show nonrandom chromosomal abnormalities, especially in larger tumors, related to mutations in cell growth regulation. Clonal expansion of leiomyoma cells precedes these chromosomal anomalies, indicating that chromosomal anomalies are an effect of growth [ 73 ]. A detailed review of studies pertaining to UL genetics appears in a subsequent chapter of this monograph. In this section, we summarize the results of epidemiologic studies of risk factors for UL, focusing on the etiologic factors mentioned above: estrogens, progesterone, growth factors, and genetic factors. Most evidence regarding risk factors comes from twenty-two studies based on surgical, clinical, or ultrasound diagnoses ( Table 2 ). Women with early onset of menses or late onset of menopause will, on the average, have increased lifetime exposure to ovulatory cycles. Because mitotic activity in the myometrium is greatest during the luteal phase of the menstrual cycle [ 74 ], a longer history of cycling would be expected to increase UL risk. In support of this, most studies have shown that UL risk increases with earlier age at menarche [ 22 , 29 , 75 – 81 ]. No studies have investigated the relation between late age at menopause and risk for UL. However, the NIEHS Fibroid Growth Study (FGS) compared UL growth rates in women approaching menopause and found that growth rates declined with premenopausal age among white women, but not black women [ 82 ]. Among women 45 years and older, the UL growth rate per 6 months was 2% for white women and 15% for black women. After menopause, women have a lower risk of developing UL [ 29 , 30 , 76 , 83 – 85 ]; pathologic studies of hysterectomy specimens found a reduction both in the size and number of UL in postmenopausal compared with premenopausal women [ 86 ]. However, the same proportion of premenopausal and postmenopausal women had physical evidence of UL [ 86 ]. The relationship between UL and menstrual cycle patterns is less clear. In the NHS II, irregular menstrual cycles and longer menstrual cycle length were associated with decreased UL risk [ 80 ], but no such associations were found in previous studies [ 79 , 87 , 88 ]. Having a child has been associated with a decreased risk of developing UL in many studies [ 75 , 77 , 78 , 80 , 85 , 88 , 89 ]. The reduction in risk ranges from 20–50% when comparing parous with nulliparous women, and risk appears to decrease with a higher number of children in most [ 30 , 75 , 77 , 80 , 85 , 89 ] but not all [ 78 ] studies. Spontaneous abortions or incomplete pregnancies appear to be unrelated to risk [ 28 , 78 , 88 , 89 ]. Women with infertility are more likely to have UL [ 29 , 77 , 89 ], particularly women with infertility at younger ages (<25 years) [ 78 , 79 ]. Even when controlling for infertility, multiparity is associated with a reduced risk of UL [ 89 , 90 , 92 ]. Older age at first term birth has been associated with a lower risk of UL in four [ 29 , 76 , 78 , 80 ] of eight studies [ 28 , 30 , 75 , 89 ]. Studies more consistently show that the longer the time since the last birth, the higher the risk of UL [ 29 , 30 , 75 , 77 , 78 , 80 , 88 ], although the association is not linear in all studies [ 78 ]. In the UFS, age at birth in the mid-reproductive years (25–29 years) was most protective against UL [ 90 ]. Direct protective effects for parity were observed in experimental data from the Eker rat [ 37 ]. Although little is known about the mechanism, several theories exist such as altered endocrine profiles following a first or second pregnancy [ 91 – 93 ], especially if initiated late in reproductive life. Similarly, pregnancy may lead to a reduction in estrogen receptor levels in myometrial tissue [ 74 ]. Alternatively, childbearing may counteract UL development through nonhormonal mechanisms. For example, reductions in collagen content and smooth muscle cell cytoplasm during the postpartum period could eliminate or reduce the size of UL [ 24 ], and ischemia during parturition and uterine remodeling could preferentially eliminate UL due to differences in vascularity compared with myometrium [ 94 , 95 ]. The inverse associations observed with later age at first birth and shorter time since last birth are consistent with a nonhormonal hypothesis of pregnancy-related elimination of UL [ 90 ]. A study that systematically screened for UL in early pregnancy and postpartum was designed to test this hypothesis [ 18 ]. Among the 171 women with a single leiomyoma in early-pregnancy, 36% of tumors were eliminated by the time of the ultrasound screen 3–6 months postpartum; tumors that were not eliminated shrank on average. The degree of elimination and shrinkage was much greater than would be expected based on data from nonpregnant women, and both small and large tumors were eliminated [ 18 ]. Breastfeeding, which suppresses ovulation and ovarian hormone production, did not mediate the pregnancy-associated elimination of UL [ 96 ]. These results are consistent with epidemiologic studies that show little, if any, protective effect of breastfeeding on UL after adjustment for parity [ 75 , 78 , 80 , 84 ]. Body mass index (BMI, kg/m 2 ) has been associated with a modest increased risk of UL in several [ 29 , 30 , 75 , 85 , 89 , 97 – 100 ] but not all [ 76 , 84 , 88 ] studies. In the UFS, a positive association was observed among black but not white women [ 101 ]. While some studies have shown a positive linear relation between BMI and UL risk [ 30 , 97 ], most positive studies have found a non-linear association, with risk increasing up through the overweight categories, and then decreasing slightly among the heaviest or obese women [ 75 , 83 , 98 , 100 , 101 ]. BMI in adolescence and young adulthood has not been associated with UL risk [ 22 , 97 , 98 , 100 ]. The peripheral conversion of androgens to estrogens that occurs in adipose tissue is unlikely to explain an association between BMI and UL because the vast majority of circulating estrogens in premenopausal women comes from the ovaries [ 102 ]. However, higher BMI is correlated with lower circulating levels of sex hormone binding globulin, potentially increasing the bioavailability of circulating estrogens and androgens in overweight and obese women [ 102 ]. Obesity-related anovulation [ 103 ] could counteract this effect by decreasing progesterone levels, thereby explaining the non-linear pattern in risk. The observed BMI association also could be due to detection bias, as pelvic examinations are less effective among obese women. U.S. prospective cohort studies have consistently shown an association between gaining weight during adulthood and increased UL risk [ 29 , 97 , 98 , 100 ]. The CTS found 16% and 23% increased risks of surgically-treated UL associated with weight gain of 10–20kg and >=20kg respectively compared with women who gained <10kg. For women who maintained weight or lost weight, there was a 13% reduced risk of UL compared with women who gained <10kg [ 29 ]. Central adiposity as measured by waist circumference or the waist-to-hip ratio was not associated with UL risk in the BWHS [ 98 ] or the UFS (unpublished data), but waist-to-hip ratio was weakly positively associated with risk in the NHS II [ 100 ]. No association has been found between height and risk of UL diagnosed by ultrasound or surgery [ 22 , 97 , 98 , 100 ]. The data are more ambiguous on physical activity, but lean towards a protective effect of exercise. In a study of former college athletes and nonathletes surveyed about their history of benign gynecologic diseases, nonathletes were more likely to report a history of benign uterine tumors [ 104 ]. No association was observed between lifetime moderate and strenuous physical activity and surgically-treated UL in the CTS [ 29 ]. By contrast, the UFS reported an inverse association between regular exercise and UL risk in both black and white women: UL was 40% lower comparing the highest (≥7 hours/week) versus lowest category (<2 hours/week) of physical activity, and a dose-response relation was observed [ 101 ]. The effect may be mediated by lower luteal phase estrogens in premenopausal women with greater physical activity [ 116 ]. Early studies suggested an inverse relation between UL and smoking [ 29 , 30 , 75 , 76 , 105 ], with risk reduction ranging from 20–50% lower among current or ever smokers relative to never smokers. However, more recent case-control [ 79 , 88 ] and prospective cohort studies [ 23 , 97 ] find no such association. In the UFS, there was a positive relation of smoking with diffuse UL but not with submucosal or intramural/subserosal UL [ 81 ]. Tobacco components may inhibit aromatase [ 106 ] and shift estradiol metabolism toward less potent forms of estrogen [ 107 , 108 ]. Conversely, components of cigarette smoke may also exert estrogen-related effects on the uterus that could promote cell proliferation [ 109 ]. Three [ 13 , 23 , 110 ] out of the four studies that have investigated the relation of alcohol intake to UL risk report modest positive associations [ 13 , 23 , 110 , 111 ]. Alcohol consumption is associated with higher endogenous levels of estradiol and estrone in some studies [ 112 , 113 ]. Although caffeine was not associated with UL in a case-control study [ 111 ], the BWHS found an increased risk of UL among the heaviest consumers of coffee (≥3 cups/day) and caffeine (≥500 mg/day) aged <35 years [ 23 ]. Coffee and caffeine consumption are associated with increased levels of early follicular phase estradiol [ 114 ] and may enhance sex steroid production [ 115 ]. A plant-based diet has been hypothesized to decrease risk of UL by reducing the bioavailability of endogenous hormones [ 116 , 117 ]. An Italian case-control study of surgically-confirmed cases examined risk of UL in relation to diet, finding inverse associations with greater intake of fruits and vegetables and positive associations with greater intake of red meat and ham [ 111 ]. Subsequently, several studies on diet and UL have been published in which validated food frequency questionnaires or nutrient biomarkers were used. The BWHS found that higher intakes of fruits and vegetables was associated with a reduced risk of UL [ 118 ]. In a subset of participants from The Uterine Leiomyomata Epidemiology Project (TULEP), urinary isoflavones and lignans were measured as biomarkers of soy intake [ 119 ]. Because soy exhibits antiestrogenic activity among those with high levels of endogenous estrogens, the authors hypothesized that soy intake would reduce UL risk. The study showed no association with isoflavones, consistent with two subsequent studies of soy intake (measured by food frequency questionnaire) and UL risk [ 110 , 120 ], even in populations where soy intake was high [ 110 ]. Lignans, found in fruits and vegetables, were associated with a lower risk of UL in TULEP, consistent with results from the Italian case-control study [ 111 ] and the BWHS [ 118 ]. Although experimental animal data show a protective effect of dietary supplementation with lycopene—a carotenoid found in tomato products and other fruits and vegetables—on incidence of UL, epidemiologic data from the NHS II and BWHS show no associations between intake of lycopene, or any other carotenoids, and risk of UL [ 36 , 118 , 121 , 122 ]. The BWHS provided the first epidemiologic evidence of reduced UL risk associated with dairy consumption [ 120 ]. UL risk was 30% lower among women consuming ≥4 versus <1 serving/day of total dairy (95% CI: 0.58–0.86; P-trend <0.001). Results were similar for high- and low-fat dairy. Dietary calcium, phosphorus, and calcium-to-phosphorus ratio (a marker of bioavailable calcium) were also inversely associated with risk [ 120 ]. In the BWHS, dietary intakes of total fat and fat subtypes were not associated with UL risk overall, although statistically significant associations were observed for specific saturated (inverse) and monounsaturated and polyunsaturated (positive) fatty acids. With respect to polyunsaturated fats, the incidence rate ratio (IRR) for the highest versus lowest quintiles of marine fatty acid intake [the sum of omega-3 (n-3) polyunsaturated fatty acids eicosapentanoic acid, docosapentaenoic acid, and docosahexaenoic acid] was 1.18 (95% CI: 1.05, 1.34; P-trend=0.005). The IRR for the highest versus lowest categories of dark-meat fish consumption was 1.13 (95% CI: 1.00, 1.28) [ 123 ]. The UFS found an increased risk of UL with increasing LH level [ 124 ], with a stronger association for larger tumors. LH shares a receptor with human chorionic gonadotropin, a hormone that stimulates uterine growth during early pregnancy. In vitro studies have found a link between IGF-1 and leiomyoma cell proliferation and gene expression. IGF-1 stimulates UL cell proliferation in culture [ 125 , 126 ]. Studies of human UL cells have found increased IGF-1 gene expression [ 127 – 129 ] and protein levels [ 130 , 131 ] relative to normal myometrial cells. However, the UFS showed no association between plasma levels of IGF-1 and UL risk [ 66 ]. BWHS investigators hypothesized that high dietary glycemic index (GI) and glycemic load (GL) would increase UL risk by increasing endogenous concentrations of IGF-1 or estrogen bioavailability [ 132 ]. However, dietary GI was not appreciably associated with risk of UL overall, and only small positive associations were observed for GL among women aged <35 years (IRR for highest versus lowest quintile: 1.18; 95% CI 1.02–1.37). Hyperinsulinemia and diabetes have been hypothesized to protect against UL risk via localized vascular dysfunction, given that UL have less vascularization than normal myometrium [ 133 ], and systemic vascular dysfunction can inhibit tumor development. In support of this, the UFS found an association of both high insulin and diabetes with a lower UL risk among black women [ 66 ]. Diabetes was also inversely associated with UL risk in the BWHS [ 134 ] and CTS [ 29 ]. Interestingly, PCOS, despite its association with hyperinsulinemia, was associated with a 65% increased risk of UL in the BWHS [ 134 ]. Other mechanisms by which PCOS could influence UL include increased levels of LH or unopposed estrogens [ 124 ]. The role of stress in the etiology of UL has only recently been studied [ 135 ]. In addition to influencing health-related behaviors that promote UL (e.g., physical inactivity, heavy alcohol consumption), stress can down-regulate the hypothalamic/pituitary synthesis of ovarian hormones, but in some circumstances up-regulate adrenal progesterone [ 135 – 137 ]. Granulosa cell tissue culture studies also show increased rather than decreased ovarian steroid secretion following exposure to stress hormones [ 138 ], and various growth factors, cytokines, and matrix metalloproteinases can be up-regulated by stress hormones [ 136 , 137 ]. In the BWHS, two measures of perceived racism were positively associated with UL, and weaker associations were found among women with higher coping skills [ 139 ]. In a cross-sectional study, a higher risk of UL was found with greater number of major life events and “stress intensity” [ 140 ]. The NHS II found a higher incidence of UL among women who experienced early-life abuse [ 141 ]; among women reporting an emotionally supportive relationship in childhood, the risk was lower, suggesting that social and emotional support may buffer the impact of stress on risk. Although the association between oral contraceptive (OC) use and UL has been studied extensively, no clear patterns have emerged. Studies have shown reduced [ 30 , 75 ], similar [ 29 , 76 , 78 , 80 , 84 , 85 , 88 , 142 , 143 ], and increased [ 144 ] risks of UL among ever users of OCs relative to never users. Results regarding status of use (i.e., current versus former use) and duration of use are similarly inconsistent [ 29 , 30 , 76 – 78 , 142 – 145 ]. Risk is not associated with time since most recent OC use [ 30 , 78 , 142 ], but two studies observed an increased risk (20–29%) among women who initiated OCs prior to 17 years of age compared with never users [ 77 , 78 ]. Because early initiation of OCs may serve as a marker for early sexual activity and exposure to sexually transmitted infections [ 146 ], these data may support an infectious etiology. OCs may also be prescribed to women with other pelvic disease (e.g., endometriosis or dysmenorrhea), thereby increasing the opportunity for incidental detection of UL. A case-control study found that use of OCs containing progestins with estrogenic properties was more common in cases than in controls [ 30 ]. However, the BWHS found no association of UL with estrogenic and progestational potency, type of progestin, or estrogen formulation (monophasic vs. biphasic/triphasic) [ 78 ]. A study in Thailand showed a strong inverse association (OR=0.4, 95% CI 0.3–0.5) between a history of DMPA use and risk of surgically-confirmed UL [ 75 ]. Risk declined with increasing duration of use, such that use for more than 5 years was associated with a 90% lower risk of UL; the inverse association weakened with increasing time since last use. The BWHS replicated this association, reporting a 40% reduced risk (95% CI 0.4–0.9) comparing current users of progestin-only injectables with non-users of hormonal contraception [ 78 ]. A cross-sectional analysis from the Study of Environment Lifestyle and Fibroids (SELF), an ultrasound screening study of young African American women, also found an inverse association between DMPA and UL (adjusted RR: 0.8, 95% CI: 0.6, 0.9) [ 40 ]. The effect of DMPA is likely mediated through the lower estradiol concentrations which resemble those of postmenopausal women; in addition, estradiol suppression increases with longer duration of DMPA use [ 147 ]. Use of exogenous hormones after menopause is associated with a higher risk of UL diagnosis in most studies. In both prospective and case-control studies, the risk of surgically-confirmed UL was increased up to 6-fold in women using estrogen or combined estrogen-progestin therapy compared with non-users [ 155 , 88 , 46 , 44 ]. Prenatal exposure to DES has been shown to cause long-term changes in estrogen-related gene expression [ 160 ] and endogenous hormones of premenopausal women [ 148 ]; thus, an association with increased risk of UL is plausible. Although an association has been found in laboratory rodents [ 149 , 150 ], the epidemiologic data are conflicting, possibly because prenatal exposure to DES is difficult to assess and such studies are prone to recall bias. One prospective cohort study, which used medical records to document exposure found no association between prenatal DES exposure and UL [ 48 ]. A second study found a 21% increased risk of UL among women who self-reported exposure to DES in the first trimester [ 151 ]. Two cross-sectional studies found a positive association between self-reported prenatal DES exposure and UL risk [ 22 , 152 ]; one found that only “probable,” but not “definite,” prenatal DES exposure was associated with UL risk, suggesting that recall bias could explain these results. To minimize the influence of reporting bias, future studies should seek medical documentation of DES exposure. The role of infection or inflammation as an etiologic factor was first proposed in the 1930s [ 153 , 154 ]. Studies show that inflammation increases the production of extracellular matrix and decreases apoptosis in UL [ 68 , 155 ], but epidemiologic studies have been inconclusive. Although 2 studies showed non-significant increases with Chlamydia [ 156 ], a recent cross-sectional ultrasound-based study found an inverse association with Chlamydia and no association with other reproductive tract infections [ 41 , 157 ]. Prospective studies are needed to clarify the temporal relationship between exposure and disease. Having an abnormal Pap test has been associated with a decreased risk of UL in cross-sectional studies from 2 different populations and a case-control study [ 41 , 95 ]. Among young African-American women, the risk of UL was 39% lower if a cervical procedure was required [ 41 ]. HPV is presumably a factor in that association, and a protective pathway has been proposed. It has been postulated that uterine injury results in UL due to disordered wound healing, similar to keloids [ 68 ]. Keloids and hypertrophic scars, which result from skin injury have similar extracellular matrix and collagen features and are more frequent in African-Americans [ 158 , 159 ]. In a cross-sectional analysis of African American women in the SELF study, self-reported keloids and hypertrophic scars were not associated with ultrasound-screened UL [ 160 ]. In an insurance database in Taiwan, keloids were rare but were associated with 2-fold increase in UL compared with women who did not have a diagnostic code for UL [ 161 ]. Several studies have found evidence of genetic predisposition to UL including familial aggregation studies [ 162 , 163 ], twin studies [ 164 , 165 ], and genetic linkage studies in families with syndromes that are associated with UL [ 166 – 168 ]. Twin studies show a strong element of heritability in women undergoing hysterectomy [ 164 , 165 ], with the concordance rate for hysterectomy for all indications in monozygotic twins being twice that of dizygotic twins [ 164 ]. Having first-degree affected relatives increases UL risk [ 162 , 169 ]. Genetic linkage analyses have identified genes that cause rare familial forms of UL. The most clinically important syndrome is hereditary leiomyomatosis and renal cell carcinoma (HLRCC) [ 170 ], an autosomal dominant disease caused by genetic mutations in the fumarate hydratase (FH) gene [ 171 – 173 ]. Several mutations in the FH gene exist, all leading to an absent, truncated, or nonfunctional protein [ 172 , 174 ], which causes loss of tumor suppression. Signs of HLRCC include UL and a family history of cutaneous leiomyomata or papillary renal cell carcinoma [ 171 ], and an increased risk of uterine sarcomas at an early age. The association of FH mutations with nonsyndromic UL has been shown consistently in white women [ 172 , 174 – 182 ], but not black women [ 179 ]. While large linkage studies offer the promise of finding common genetic variants of strong effect (>3–4-fold increase risk per copy) [ 183 – 185 ], they have low power to find genetic variants of weaker effect (1% in a given population) that influence risk of UL. Most studies of genetic polymorphisms in relation to UL have focused on genes involved in steroidogenesis because studies suggest endogenous sex hormones are important in the development and progression of disease. However, candidate gene studies have produced inconsistent findings, which may be attributable to small sample size and inadequately-characterized study populations [ 186 ]. The first ever genome-wide association study (GWAS) of UL was conducted in a Japanese population [ 187 ], finding three significant loci on chromosomes 10q24.33, 22q13.1 and 11p15.5. A subsequent GWAS in women of European descent found that SNPs in the FASN gene were associated with UL, but did not replicate the Japanese GWAS findings [ 188 ], nor did the BWHS among African Americans [ 189 ]. However, the BioVU and Right From the Start cohorts replicated two SNP associations from the Japanese GWAS among European Americans (blocked early in transport 1 homolog (BET1L) rs2280543, and trinucleotide repeat containing 6B (TNRC6B) rs12484776) [ 190 , 191 ]. In the BWHS, admixture mapping analyses showed suggestive evidence of association at chromosomes 2, 4, and 10 (2q37, 4p16.1, and 10q26) [ 189 ], with the region in chromosome 2 being replicated in the UFS [ 192 ]. Women diagnosed with UL are more likely to be married, have more years of education, and have an occupation categorized as “professional” [ 12 , 13 , 75 , 83 ]. These associations could be explained by greater access to medical care and opportunity for UL detection. A positive association was found between high blood pressure and UL in several epidemiologic reports based on cross-sectional [ 193 , 194 ], case-control [ 99 , 156 ], and prospective cohort [ 29 , 195 – 198 ] study designs. In a population-based case-control study, hypertension was not higher preoperatively among women undergoing hysterectomy for UL compared with aged-matched referents [ 199 ]. However, all but two of these studies [ 156 , 196 ] were limited to surgical cases of UL. In the NHS II [ 196 ], the association between self-reported blood pressure and risk of UL appeared to be strongest for surgical cases (N=1,661). In the BWHS, physician-diagnosed hypertension was associated with UL confirmed by hysterectomy but not by ultrasound or other surgery [ 197 ]. Whether the association is due to detection bias or shared etiology is unclear. Environmental exposures may affect UL risk via multiple mechanisms, including endocrine disruption. In a cross-sectional study, no association was found between blood levels of lead, mercury, and cadmium, and self-reported UL history [ 200 ]. High serum levels of dioxin measured after a chemical explosion in Seveso, Italy were associated with reduced UL risk [ 26 ]. The inverse association may be explained by dioxin’s antiestrogen effects and its ability to limit extracellular matrix production via TGF-β pathways [ 201 ]. Phthalates, ubiquitous chemicals found in consumer products, are reproductive toxicants in animals [ 202 ]. Of the four epidemiologic studies that have assessed phthalates in relation to UL [ 203 – 206 ], two showed an increased risk with higher exposure to some phthalates [ 204 , 205 ]. In another study, self-reported UL were positively associated with serum polychlorinated biphenyl (PCB) levels and groupings of estrogenic, antiestrogenic, and dioxin-like PCBs [ 207 ]. Two subsequent studies also found a higher UL prevalence among those with greater exposure to PCBs [ 207 – 209 ]. Urinary levels of bisphenol A, which also has endocrine-disrupting properties, have been positively associated with UL prevalence in three studies [ 210 – 212 ] but not a fourth study [ 206 ]. Existing studies are limited by small sample size [ 203 , 204 , 209 – 212 ], uncertain temporality due to the use of cross-sectional [ 205 ] or case-control designs [ 203 , 204 , 206 , 208 – 210 ], and suboptimal measurement of environmental chemicals [ 203 , 211 ] and UL [ 204 , 205 , 207 – 212 ]. Few data have been reported on the frequency and predictors of surgical or pharmacologic interventions among women diagnosed with UL. In a study confined to women whose uteri were ≥8 weeks gestation, 25% of cases had surgery within one year of diagnosis [ 213 ]. In a study of cases with a broader range of uterine sizes, approximately 26% had surgery within 5 years; risk of progressing to hysterectomy was inversely related to recommended therapeutic use of OCs or progestins [ 214 ]. The 3-year cumulative incidence for hysterectomy was 83% among women aged >35 years who had uteri >8 weeks size, and who had at least one of the other characteristics related to increased risk of hysterectomy [ 214 ]. In the FGS, 44% of black women and 40% of white women chose treatment during the study. Symptoms of heavy bleeding and pain were related to choosing intervention, while size and number of UL were not related [ 215 ]. Few studies have investigated the predictors of choosing a uterine-sparing procedure over a hysterectomy, although geography has been shown to play a role [ 216 ]. In a national survey of women with UL, African American women were nearly 3-fold more likely to value treatment options that preserved fertility than white women [ 217 ]. Overall in this cohort, 79% valued less invasive therapy, which was stronger among the younger women [ 218 ].

UL are a common cause of reproductive health problems and medical care utilization. Clarifying the etiology of UL initiation and growth is essential to learning about pathways for primary and secondary prevention. While estrogen and progesterone are almost certainly involved in UL pathogenesis, the in vivo mechanisms through which these hormones act are not well understood. Few modifiable risk factors have been identified. Further research incorporating the steroid hormone and extracellular matrix production pathways is needed. Epidemiologic studies that evaluate molecular pathways by incorporating biologic measures of exposure and concrete disease assessment will be essential to making stronger inferences regarding specific risk factors and mechanisms. Although greater knowledge about tumor onset may provide strategies for primary prevention, identifying risk factors for tumor growth and symptoms may decrease the adverse effects and public health burden of these tumors. It is valuable to stratify cases according to ultrasonographic or molecular characteristics to identify UL subtypes that are associated with particular exposures. Alternative etiologic hypotheses based on epidemiologic associations need to be explored. For example, similarities between smooth muscle cell proliferation in UL and atheromas, and reported associations between hypertension and surgically-diagnosed UL, suggest the potential for shared etiologic mechanisms with coronary heart disease. The occurrence of leiomyomata outside of the uterus in patients immunocompromised due to HIV infection suggests possible roles for infectious agents or immunological factors. These hypotheses should be assessed with direct testing for infection or inflammation and screening for UL onset. Additional epidemiologic studies of nutritional factors prior to known tumor onset would be informative, particularly factors that can influence the endogenous hormonal millieu. In theory, promising advances also might result from studies that seek to explain behavioral, social, and biologic factors that underlie differences in UL development and growth among women of different ethnic origins. For example, differences in vitamin D status should be explored given intriguing preliminary evidence of an association [ 219 – 223 ]. New cohorts or those of young women currently followed for other reasons should be pursued. For example, the prospective study of UL among young African-American women from the Detroit area (SELF) was initiated in 2012 and will provide invaluable information (PI: Baird), specifically the extent to which vitamin D deficiency influences UL risk. Finally, studies focused on medical utilization and clinical outcomes are needed to identify characteristics of patients and their providers that influence use of different treatments for UL at different stages of development. A national UL registry will assess factors that affect treatment choices as well as outcomes of treatment options ( clinicaltrials.gov NCT02260752 ). Studies should attempt to determine the extent to which patient characteristics, ultrasonographic features, and physiologic measures are related to UL progression from clinical diagnosis to surgical therapy, particularly hysterectomy. For example, one study suggested that increased tumor vascularity, as measured by Doppler ultrasonography, is strongly associated with increased tumor growth [ 224 ]. Similar studies, augmented by analyses of molecular features of excised UL, may help define predictors of recurrence risk following myomectomy. Results from these studies could provide patients and health care providers with information that will improve the management of UL.

Given the high frequency of asymptomatic UL, the most valid estimates of their prevalence and incidence come from epidemiologic studies that use universal ultrasound screening [ 9 , 14 , 15 , 17 , 25 , 26 ]. However, the best measures of disease burden and healthcare expenditures come from studies of hospital discharge data or self-reported rates of clinical diagnoses. Incidence rates of UL diagnoses in U.S. populations are based largely on data from national hospital discharge studies [ 4 , 27 ], nationally-representative studies [ 28 ], and large prospective cohort studies [ 12 , 13 , 29 ]. In these studies, rates vary according to case definition, ranging from 12.8 per 1,000 person-years for all diagnoses (by pelvic exam, ultrasound, or hysterectomy) to approximately 2.0 per 1,000 person-years for hysterectomy-confirmed cases. During 1998 through 2005, the rate of hospitalizations for UL among women aged 15–54 years was 2.8 cases per 1,000 person-years ( Table 1 ). The vast majority of hospitalizations for UL involved a surgical procedure (94.4%), most commonly hysterectomy (79.2%) [ 4 ]. UL tend to increase with age through the reproductive years and decline in the postmenopausal years [ 4 , 13 , 27 , 29 – 31 ]. During 1998–2005, rates of inpatient hospitalization for UL in the U.S. increased steadily by age until reaching a peak among women aged 45–49 years (6.3 per 1,000 person-years), and then declined among women aged 50–54 years (3.2 per 1,000 person-years) ( Table 1 ) [ 4 ]. Age-specific prevalence estimates for UL, regardless of symptomatology, come from five ultrasound-screening studies ( Figure 1 ). They also show an increase in prevalence of UL with increasing premenopausal age. Incidence of UL is 2–3 times greater among black than white women [ 13 , 14 , 28 ], after adjustment for age and other risk factors. The higher incidence among black women is evident at nearly all ages [ 13 , 27 ]. Rates of hospitalization for UL are about 5.3 per 1,000 person-years for black women and 2.4 per 1,000 person-years for white women [ 27 ]. The UFS was the first definitive study to confirm the black-white difference in incidence, showing that the cumulative incidence by age 50 (measure of lifetime risk) was nearly 70% for white women and >80% for black women [ 14 ]. Black women had nearly three times the age-specific cumulative incidence of white women. When restricted to clinically-significant UL (≥9-week gestation uterus, at least one >4 cm tumor, or at least one submucosal leiomyoma), estimates were 50% for black women and 25% for white women [ 14 ]. Ultrasound data on younger women come from an early-pregnancy screening study [ 17 ], demonstrating an age at onset about ten years earlier among black than white women. The cumulative incidence of UL steadily and rapidly increases for 10 years beginning at about age 25 years for black women and about age 35 years for white women ( Figure 1 ). Similarly, an ultrasound screening study of asymptomatic women 18 to 30 years found a prevalence of 26% among black women and 7% among white women [ 13 ]. Other findings also support a black-white difference in age at onset and disease severity. Among women undergoing hysterectomy for UL, mean ages at first diagnosis and hysterectomy were lower among black women than white women [ 8 , 32 ], and black women had longer hospital stays and higher medical costs per day [ 3 ]. The reason for the more frequent and earlier diagnoses of UL among black women is unclear. The excess does not seem to be attributable to differences in the types and severity of symptoms, use of health care, or prevalence of putative risk factors [ 8 , 13 ]. In both the Nurses’ Health Study (NHS II) and UFS, adjustment for several known or suspected risk factors did not substantially attenuate the three-fold difference in risk between black and white women [ 13 , 14 ]. The observation that black women have more UL, larger tumors, and heavier uterine weight than white women [ 8 , 13 , 14 ] suggests a genetic basis for the racial difference. However, yet-to-be identified or elucidated risk factors such as vitamin D deficiency, reproductive tract infections, psychosocial stessors, or other environmental factors cannot be ruled out as possible explanations.

Uterine leiomyomata (UL), commonly called “fibroids,” are benign neoplasms of uterine smooth muscle. Although they are often asymptomatic, UL can cause excessive menstrual bleeding, pelvic pain, and other symptoms that seriously affect a woman’s quality of life. Symptomatic UL may require medical or surgical intervention and increased medical utilization; in the U.S., they account for nearly 30% of all hysterectomies among women ages 18–44 years [ 1 ] and $9.4 billion in annual health care costs [ 2 ]. From 1993 to 2003, inpatient admissions for UL in U.S. hospitals increased by more than 20% [ 3 ], and UL remain the most common diagnosis among inpatient hospitalizations for gynecologic conditions in women 15–54 years of age [ 4 ]. During 1997–2005, the percentage of hysterectomies due to UL decreased from 31.4% to 26.9% [ 1 ]. However, rates of alternative surgeries, such as myomectomy and uterine artery embolization, have increased during the same period [ 3 , 5 , 6 ]. Despite their substantial impact on gynecologic morbidity, relatively little is known about the etiology of UL.